US biopharmaceutical company AbbVie said Tuesday it would buy Botox-maker Allergan for about $63 billion, moving to diversify its product line as the industry faces pressure on drug prices.
US biopharma AbbVie to buy Botox maker Allergan for $63 billion
More from Industry NewsMore posts in Industry News »
- Sanofi and Translate Bio start clinical trial for mRNA flu vaccine
- Dr Reddy’s Laboratories launches Icosapent Ethyl Capsules in US
- Bharat Biotech’s Covaxin gets SEC approval on its Phase 3 trials efficacy data
- Covid-19 has highlighted the Indian pharma industry’s potential in transforming into an innovation hub: Sudarshan Jain